Loading...
Loading...
Cardium Therapeutics
CXM today announced an agreement with UK-based Angel Biomedical Limited, a subsidiary of Angel Biotechnology Holdings plc
ABH, a global biopharmaceutical contract manufacturer, covering the manufacture of formulated collagen for Cardium's Excellagen® product, which was recently cleared for marketing by the U.S. Food and Drug Administration (FDA).
Excellagen is a professional-use high molecular weight fibrillar bovine Type I topical gel (2.6%) specifically engineered as an adjunct to debridement for the management of diabetic foot ulcers and other dermal wounds.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in